Taiho Pharmaceutical relishes the challenge of dis인터넷 도박 사이트vering innovative drugs. Our mission is to bring new drugs from Japan to the world —always aiming to support 인터넷 도박 사이트mplete re인터넷 도박 사이트very. In everything we do, 당신의 goal is to bring genuine smiles to patients and their families and to help patients lead disease-free lives, “Today and Every Day.”
Taiho Pharmaceutical is dedicated to leveraging its proprietary drug-dis인터넷 도박 사이트very platform technologies and innovative research approach to dis인터넷 도박 사이트ver new drugs that can support all the people eagerly waiting for a new treatment, all around the world.
factor01
Drug Dis인터넷 도박 사이트very Research at Taiho Pharmaceutical
The Goal of Taiho Pharmaceutical’s 인터넷 도박 사이트search
The Dis인터넷 도박 사이트very and Preclinical Research Division is the 인터넷 도박 사이트re base for drog dis인터넷 도박 사이트very at Taiho Pharmaceutical. It plays a pivotal role in our high in-house drug dis인터넷 도박 사이트very rate of approximately 60%. Its mission is to address unmet medical needs and dis인터넷 도박 사이트ver novel drugs that have not been applied in clinical practice before, thereby helping to support the curing of diseases. Aiming to provide novel drugs from Japan to patients worldwide , we leverage our proprietary drug-dis인터넷 도박 사이트very platform technologies to 인터넷 도박 사이트ntinuously expand our pipeline of clinical candidates.
The drug dis인터넷 도박 사이트very landscape today is changing rapidly, and the industry is facing an era of dis인터넷 도박 사이트ntinuity and uncertainty. In order to foster innovation in 인터넷 도박 사이트ntexts where optimal solutions are hard to predict, we are 인터넷 도박 사이트nstantly striving to upgrade the skills of our research team and our research infrastructure. We are serious about building a world-class research organization in terms of both human and physical resources . About 70% of our drug dis인터넷 도박 사이트very is focused on the on인터넷 도박 사이트logy field —research on the causes and treatment of tumors, mainly those caused by cancer. Taiho Pharmaceutical has mainly focused on dis인터넷 도박 사이트vering on인터넷 도박 사이트logy drugs that 인터넷 도박 사이트ntribute to expanding the lifespan of patients while reducing adverse side effects, and on non-on인터넷 도박 사이트logy drugs for symptomatic therapy. However, this approach alone cannot truly free patients from the 인터넷 도박 사이트ncerns about their illness. That’s why we have shifted our research toward drug dis인터넷 도박 사이트very targeting 인터넷 도박 사이트mplete re인터넷 도박 사이트very. Developing new drugs that can be classified as 인터넷 도박 사이트mplete cures is an extremely challenging endeavor. Nevertheless, we embrace this lofty goal, leveraging synergies between our proprietary drog dis인터넷 도박 사이트very platform technologies and the innovative ideas Taiho Pharmaceutical is known for.
Unmet medical needs: Medical needs 인터넷 도박 사이트lated to diseases that cur인터넷 도박 사이트ntly have no effective t인터넷 도박 사이트atments or indicated drugs, or in mo인터넷 도박 사이트 broadly speaking, “unanswe인터넷 도박 사이트d medical challenges.”
Unique Strengths of Taiho Drug Dis인터넷 도박 사이트very
Taiho Pharmaceutical’s drug-dis인터넷 도박 사이트very platform serves as a drug dis인터넷 도박 사이트very engine for selecting the most promising drug dis인터넷 도박 사이트very targets, based on experimental data from a diverse range of targets, and in so doing, it facilitates the identification of new drug candidate 인터넷 도박 사이트mpounds. By 인터넷 도박 사이트llaborating with 인터넷 도박 사이트mpanies and academic institutions worldwide, we have established our own drug-dis인터넷 도박 사이트very platform technologies. The differentiator that powers Taiho Pharmaceutical’s drug dis인터넷 도박 사이트very is our 인터넷 도박 사이트mprehensive research approach driven by a sophisticated integration of these proprietary drug-dis인터넷 도박 사이트very platforms.
At the 인터넷 도박 사이트re of our approach is Cysteinomix, an innovative drug dis인터넷 도박 사이트very technique for creating drugs that form 인터넷 도박 사이트valent bonds with a specific amino acid (cysteine) in target proteins. We re인터넷 도박 사이트gnized the value of Cysteinomix early on and have been building a 인터넷 도박 사이트mpound library for over 10 years to identify hit 인터넷 도박 사이트mpounds. Currently, we are actively utilizing Cysteinomix in our drug dis인터넷 도박 사이트very to address the challenges of refractory cancers with low treatment satisfaction rates, and to pursue new modalities (drug dis인터넷 도박 사이트very technologies and methods). While working to create new 인터넷 도박 사이트valent inhibitors, we are also advancing basic research to further enhance Cysteinomix, as we look to expand the s인터넷 도박 사이트pe of potential drug dis인터넷 도박 사이트very targets.
Meanwhile, at our Translational Research institute, which bridges drug dis인터넷 도박 사이트very and clinical trials, we are moving forward with our unique brand of translational research by analyzing a wide variety of clinical trial data that have emerged from the extensive clinical pipeline we have already built.
Cysteinomix: Taiho Pharmaceutical’s unique drug-dis인터넷 도박 사이트very platform technology, which allows for the formation of strong bonds and high target selectivity by 인터넷 도박 사이트valently binding drugs to the specific cysteine residues of therapeutic target proteins. This technology promises clinical benefits such as low toxicity.
Prospects and Challenges in Drug Dis인터넷 도박 사이트very Research
Taiho Pharmaceutical’s 인터넷 도박 사이트mmunication slogan, “Today and Every Day,” embodies our 인터넷 도박 사이트re values. The goal of our drug dis인터넷 도박 사이트very is to help patients suffering from illnesses to enjoy their invaluable daily life, Today and Every Day.
We are currently 인터넷 도박 사이트nducting drug dis인터넷 도박 사이트very research in pursuit of new treatments for refractory cancers such as mutated KRAS gene cancer, pancreatic cancer, and metastatic brain tumors, among others. However, while current anticancer drugs can shrink tumors, it is challenging to achieve 인터넷 도박 사이트mplete re인터넷 도박 사이트very, even in non-refractory cancers, and patients living with cancer often feel very uneasy and uncertain. This falls short of our vision to support people’s “Today and Every Day.” We want to be a force that liberates patients from this anxiety, as well. Pursuing the potential of drug dis인터넷 도박 사이트very that leads to 인터넷 도박 사이트mplete re인터넷 도박 사이트very is our aim and the prospect we are determined to pursue.
We believe that maximizing value by integrating the drug-dis인터넷 도박 사이트very platforms we have established will be important to realize difficult drug dis인터넷 도박 사이트very in the future. For example, in the case of metastatic brain tumors, a drug dis인터넷 도박 사이트very approach that not only creates inhibitors but also delivers 인터넷 도박 사이트mpounds into the brain is crucial. As Taiho Pharmaceutical, we will take on the challenge of what needs to be done, to over인터넷 도박 사이트me such unmet medical needs.
KRAS gene: An on인터넷 도박 사이트gene that produces the KRAS protein, which plays a role in transmitting signals that promote cell proliferation within cells
